Objective:

To assess the cardioprotective effects of aegeline in an experimental myocardial infarction model.

Approach:

• Experimental Model: Isoproterenol (ISO) was used to induce acute myocardial infarction in rats, followed by administration of aegeline.
• Dosing: Aegeline was administered at doses of 5 and 10 mg on the 29th and 30th days, respectively.
• Biochemical and Histopathological Analysis: Assessment of myocardial damage, oxidative stress markers, inflammatory indicators, and apoptotic expression.
• Molecular Docking: Used AutoDock Vina to evaluate binding affinity of aegeline to cardiac proteins.
• Molecular Dynamics Simulations: Conducted to support docking findings and analyze stability of protein-ligand interactions.

Key Findings:

• Aegeline exhibited cardioprotective properties against ISO-induced myocardial damage, as evidenced by improved histopathological features and reduced myocardial damage.
• Aegeline reduced oxidative stress and inflammation markers, including specific biochemical indicators.
• Molecular docking revealed strong binding affinity of aegeline for CK-MB, with additional targets identified.
• No adverse effects on liver or kidney function were observed.

Interpretation:

Aegeline may attenuate myocardial injury through mechanisms involving oxidative stress reduction, inflammation modulation, and apoptosis inhibition.

Limitations:

• The study was conducted in an animal model, which may not fully replicate human conditions.
• Further studies are needed to explore the long-term effects and safety of aegeline.

Conclusion:

Aegeline demonstrates cardioprotective effects in experimental myocardial injury, supported by biochemical, histopathological, and computational analyses.